Iron Chelation as Novel Treatment for Interstitial Cystitis.
Administration, Intravesical
Animals
Anti-Inflammatory Agents
/ administration & dosage
Antioxidants
/ administration & dosage
Cystitis, Interstitial
/ drug therapy
Humans
Inflammation Mediators
/ metabolism
Iron Chelating Agents
/ administration & dosage
Oxidative Stress
/ drug effects
Reactive Oxygen Species
/ metabolism
Urinary Bladder
/ drug effects
Interstitial cystitis
Iron
Iron chelation
Reactive oxygen species
Journal
Pharmacology
ISSN: 1423-0313
Titre abrégé: Pharmacology
Pays: Switzerland
ID NLM: 0152016
Informations de publication
Date de publication:
2019
2019
Historique:
received:
29
11
2018
accepted:
07
12
2018
pubmed:
30
1
2019
medline:
15
3
2019
entrez:
30
1
2019
Statut:
ppublish
Résumé
Interstitial cystitis (IC) is a highly prevalent debilitating disease, with its cardinal symptoms being severe pain, urinary urgency and frequency. The associated pain may eventually lead as a last resort to removal of the bladder. Though the initial trigger for IC remains largely unknown, we propose novel iron chelators as a possible new treatment for this disease. Iron is a mandatory component for the generation of reactive oxygen species (ROS). A substantial decrease in ROS production and thus inflammation can be achieved by effectively sequestering host iron, which we believe may improve outcome and quality of life in IC patients. Novel iron chelators could be used via the intravesical route to reduce or attenuate inflammation by effectively sequestering host iron, thus preventing the production of ROS via the Fenton and Haber-Weiss reactions.
Identifiants
pubmed: 30695781
pii: 000496089
doi: 10.1159/000496089
doi:
Substances chimiques
Anti-Inflammatory Agents
0
Antioxidants
0
Inflammation Mediators
0
Iron Chelating Agents
0
Reactive Oxygen Species
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
159-162Informations de copyright
© 2019 S. Karger AG, Basel.